Human immunodeficiency virus (HIV) associated lipodystrophy: The prevalence, severity and phenotypes in patients on highly active anti-retroviral therapy (HAART) in Kenya
Date
2013Author
McLigeyo, Angela Awino
Lule, Godfrey
Otieno, Fredrick C F
Kayima, Joshua Kyateesa
Omonge, Enoch
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Highly active antiretroviral therapy (HAART) is widely accessible to human immunodeficiency virus
(HIV)-infected individuals in Kenya. Their long term use is associated with chronic complications such
as lipodystrophy which may lead to stigmatization, reduced self esteem and poor adherence to HAART.
This cross-sectional study described the prevalence of lipodystrophy, the phenotypes and severity
among adult HIV infected patients on chronic HAART at a HIV clinic in Kenya. Data were collected using
an investigator administered questionnaire and anthropometric measurements done using a protocol
based on the Third National Health and Nutrition Examination Survey. The prevalence of lipodystrophy
was 51.3% (confidence interval (CI) 45.6 to 57.6). Lipoatrophy occurred in 44%, lipohypertrophy in 15%
and mixed syndrome in 41% of patients with lipodystrophy. Facial atrophy occurred in 75.7% of patients
with lipodystrophy, upper limb atrophy in 48.5%, and lower limb atrophy in 36.8%. Abdominal obesity
occurred in 40.4% of patients with lipodystrophy, breast enlargement in 30.9% and dorsocervical fat
accumulation in 5.1%. Most patients had severe lipoatrophy, whereas lipohypertrophy was described as
mild to moderate using the HIV out-patient study (HOPS) scale. HIV associated lipodystrophy was
common in HIV-infected patients on chronic HAART. The main phenotype was lipoatrophy which
majority of the patients described as severe.
Citation
Journal of AIDS and HIV Research Vol. 5(4), pp. 107-113, April, 2013Publisher
Department of Clinical Medicine and Therapeutics
Subject
abdominalobesity
nutrition surveys
highly active anti-retroviral therapy (HAART)
Lipodystrophy
Collections
- Faculty of Health Sciences (FHS) [10377]